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            Pancreatic ductal adenocarcinoma (PDAC) has the poorest five-year survival rate 
of any cancer. Currently, there are no effective diagnostics or chemotherapeutics. Surgical 
resection is the only curative therapy. However, most patients experience recurrence due 
largely to challenges in assessing tumor margin status in the operating room. Molecular 
probes that selectively highlight pancreatic cancer tissue, having the potential to improve 
PDAC margin assessment intraoperatively, are urgently needed. In this work, a series of 
red and near-infrared fluorescent probes is reported. Two were found to distribute to 
normal pancreas following systemic administration. One selectively accumulates in 
genetically modified mouse models of PDAC, providing cancer-specific fluorescence. In 
contrast to the small molecule probes reported previously, it possesses inherent affinity for 
PDAC cells and tissue, and thus does not require conjugation to targeting agents. 
Moreover, the probe exhibits intracellular accumulation and enables visualization of four 
levels of structure including the whole organ, tissue, individual cells and subcellular 
organelles. It can thus promote new strategies for precision image-guided surgery, 
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CHAPTER 1. INTRODUCTION AND PROBE DESIGN 
 
Approximately 53,000 people will be diagnosed with pancreatic cancer (PC) in the 
US in 2016, and will have a post-diagnosis life expectancy of 5 to 7 months.1 Pancreatic 
cancer is projected to become the second leading cause of cancer-related death by 2030.2 
Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent form of PC. Current 
screening for PDAC using techniques such as MRI and CT is relatively expensive and 
ineffective, as over half of all cases are diagnosed after metastasis has occurred, limiting 
treatment options. Surgical resection is the treatment of choice because chemotherapy and 
radiation therapy do not significantly improve life expectancy.3 Unfortunately, surgical 
resection is only possible in 15-20% of cases.4 Moreover, to date there is no intraoperative 
guidance to differentiate malignant pancreas from normal pancreatic tissues. PC and 
healthy tissue are currently distinguished through white light visualization and palpation in 
the operating room as well as by rapid frozen section analysis while the surgical resection 
is in progress.5 However, 75% of patients are left with residual disease from margins not 
assessed by frozen section analysis, false negative assessments, and microscopic 
metastases not detected at the time of surgery.6  
1.1       Fluorescence Image Guided Surgery for PDAC 
Fluorescence-guided surgery to aid in the precise visualization of malignant tissue 
and cancer margins cannot be used for PDAC because a targeted contrast agent for PC is 
not available. Commercially available fluorescent dyes, including the only FDA-approved 
fluorescent contrast agents, indocyanine green (ICG), methylene blue (MB) and 
 2 
fluorescein, exhibit non-specific fluorescence and largely act as blood pool agents. MB has 
previously been used to image insulinoma, a rare form of PC compared to PDAC, in a 
genetically modified mouse model. Although MB provided specificity for insulinoma, the 
signal-to-background ratio (SBR) was relatively low.7 In a clinical setting, both MB and 
ICG have been studied for intraoperative PC imaging. MB was used to identify a solitary 
fibrous tumor of the pancreas, an extremely rare non-adenocarcinoma pancreatic tumor.8 
No clear tumor-to-pancreas contrast was observed in patients undergoing 
pancreaticoduodenectomy using ICG as a contrast agent.9 Because there is no PDAC-
specific contrast reagent in clinical trials or approved for clinical use,10-17 we have 
developed a library of systematically-modified xanthene fluorescent dyes with scaffold 
similarity to MB to contribute to the development of PDAC tumor-specific contrast agents.  
1.2       Probe Design for PDAC Imaging 
One of the main challenges in PDAC therapy is drug delivery, and is largely 
attributed to the hypovascular and fibrotic tumor microenvironment.18  Thus, in order to 
attain desirable PDAC-selective accumulation and SBR we have synthesized a focused 
library of systematically-modified 1-substituted benzo[c]xanthene fluorophores (Fig. 1.1) 
to begin to define factors modulating in vivo biodistribution19 such as probe size, 
lipophilicity, solubility and ionization state.20-23 To minimize the effects of 
autofluorescence, these compounds were designed to exhibit significant bathochromic 
shifts compared to traditional long wavelength 3-substitued benzo[c]xanthenes via the 
formal repositioning of polar groups.24-27 Herein, we report two fluorescent small molecule 
molecular probes (2 and 12) which distribute to normal pancreas following systemic 
administration. More importantly, molecular probe 12 shows selective uptake in 
 3 
genetically modified mouse models of PDAC tumor, in addition to targeting cancerous 
epithelial cells through accumulation in the mitochondria. 
 
 
Figure 1.1  1-substituted benzo[c]xanthene library. 
 
 
1.3        Energy Levels and Depiction of Frontier Molecular Orbitals, Calculated 
Absorption Spectra and Physicochemical Properties 1-substituted Benzo[c]xanthene 
Library 
Compounds 1-13 (Fig. 1.1) were designed taking into account uptake and related 
“drug-like” properties that can be used as quantitative descriptors for predicting and 
optimizing biodistribution and tissue targeting.28 The predicted absorption spectra and 
physicochemical properties of 1-13 are shown in Fig. 1.2-1.4. In summary, predicted 
absorption spectra show peaks between 400 to 650 nm, log D values are within 0.5 and 5, 
molecular weights are between 400 and 500 g/mol, each compound has 0-4 hydrogen bond 
donors and less than 10 hydrogen bond acceptors, and polar surface areas are all less than 
140 Å2, in keeping with requirements to be considered for tissue targeting according to the 
Lipinski29 and Veber rules.30 
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Figure 1.2  Energy levels and depiction of frontier molecular orbitals (HOMO and 




Figure 1.3  Energy levels and depiction of frontier molecular orbitals (HOMO and 
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Figure 1.4  Energy levels and depiction of frontier molecular orbitals (HOMO and 
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CHAPTER 2.  SYNTHESIS 
 
Unless otherwise indicated, all commercially available starting materials were used 
directly without further purification. Silica gel Sorbent Technologies 32-63 m was used 
for flash column chromatography. 1H- and 13C NMR spectra were obtained on either a 
ARX-400 or ARX 600 Advance Bruker spectrometer. Chemical shifts () are given in ppm 
relative to DMSO-d6 (2.50 ppm, 1H, 39.52 13C) unless otherwise indicated. MS (HRMS, 
ESI) spectra were obtained at the PSU Bioanalytical Mass Spectrometry Facility on a 
ThermoElectron LTQ-Orbitrap high resolution mass spectrometer with a dedicated Accela 
HPLC system. Compounds 1 and 2 were synthesized as described in the literature.18  
 
2.1       Synthesis of 2-(2,4-dihydroxybenzoyl)benzoic acid, 15. 
NaOH (50 g, 1.25 mol) is dissolved in 100 mL of DI water while cooling in an ice 
bath. Fluorescein (14) is added in one portion and the mixture is refluxed 5h. The mixture 
is cooled down to room temperature and neutralized to pH 7 using concentrated HCl. The 
mixture is treated with 2% NaHCO3 to dissolve the solid formed, and then extracted with 
ethyl ether (3 × 100 mL). The aqueous phase is acidified to pH 2 using concentrated HCl, 
then extracted with ethyl ether (300 mL). The ethyl ether is evaporated to leave a brown 
residue. The target compound 15 is isolated by recrystallization from water. Yield: 4.35 g, 
56%. 1H NMR (400 MHz, DMSO) δ 13.19 (s, 1H), 12.24 (s, 1H), 10.71 (s, 1H), 8.00 (dd, 
 7 
J = 7.7, 0.9 Hz, 1H), 7.74 – 7.67 (m, 1H), 7.65-7.61 (m, 1H), 7.42 (dd, J = 7.5, 1.0 Hz, 1H), 
6.95 – 6.90 (m, 1H), 6.33 (d, J = 2.3 Hz, 1H), 6.29 (dd, J = 8.7, 2.3 Hz, 1H). 13C NMR 
(101 MHz, DMSO) δ 200.51, 166.76, 165.01, 164.42, 140.00, 134.75, 132.32, 129.99, 
129.74, 129.48, 127.45, 113.29, 108.34, 102.55.  HR ESI [M + H]+ m/z 259.0602, calc. for 
C14H11O5 259.0600. 
 
2.2       Synthesis of 2-(4-amino-2-hydroxybenzoyl)benzoic acid, 17.  
Rhodamine 110 hydrochloride (16) (0.2 g, 0.545 mmol) is mixed with NaOH 
(0.375g, 9.27 mmol) and 180 μL of water. The mixture is stirred and heated at 160 oC for 
2 h, 0.5 mL of 50% NaOH is added in one portion and the mixture heated and stirred at 
160 oC for an additional 1 h. The mixture is allowed to cool down to room temperature and 
diluted with 10 mL of water. The mixture is acidified to pH 1 with concentrated HCl. The 
resulting mixture is extracted with ethyl ether (2 × 50 mL), the organic extracts are 
combined, dried over anhydrous Na2SO4, filtered and the solvent evaporated under vacuum 
to leave 17 as a pale yellow solid.  Yield: 0.130 g, 93%. 1H NMR (400 MHz, DMSO) δ 
13.01 (s, 1H), 12.59 (s, 1H), 7.95 (dd, J = 7.7, 1.0 Hz, 1H), 7.67 (td, J = 7.5, 1.4 Hz, 1H), 
7.60 (td, J = 7.6, 1.4 Hz, 1H), 7.36 (dd, J = 7.5, 1.0 Hz, 1H), 6.71 (d, J = 8.6 Hz, 1H), 6.44 
(s, 2H), 6.05 – 5.97 (m, 2H). 13C NMR (101 MHz, DMSO) δ 198.31, 166.92, 164.98, 
156.82, 140.07, 134.48, 131.95, 129.84, 129.69, 129.31, 127.68, 109.79, 106.48, 98.16.  
 8 
HR ESI [M + H]+ m/z 258.0754, calc for C14H12NO4 258.0760; HR ESI [M + Na]+ m/z 
280.0575, calc. for C14H11NO4Na+ 280.0580. 
 
2.3       Synthesis of 2-(4-(dimethylamino)-2-hydroxybenzoyl)benzoic acid, 20. 
3-dimethyl amino phenol (18) (5 g, 36.44 mmol) and phthalic anhydride (19) (5.39 
g, 36.44 mmol) are dissolved in 150 mL of toluene and refluxed 18 h. The solvent is 
evaporated under vacuum to leave a purple residue. The residue is dissolved in ethyl acetate 
and the mixture passed through a plug of silica gel using EtOAc:Hexanes 1:1, 
EtOAc:Hexanes 3:1, and EtOAc for elution; 4.32 g, 42% of 20 are obtained. 1H NMR (400 
MHz, CDCl3) δ 12.51 (s, 1H), 8.09 (dd, J = 7.9, 0.9 Hz, 1H), 7.66 – 7.59 (m, 1H), 7.53 (td, 
J = 7.7, 1.3 Hz, 1H), 7.35 (dd, J = 7.5, 0.9 Hz, 1H), 6.88 (d, J = 9.1 Hz, 1H), 6.15 (d, J = 
2.5 Hz, 1H), 6.06 (dd, J = 9.1, 2.5 Hz, 1H), 3.02 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 
198.78, 170.69, 165.29, 156.10, 141.35, 134.44, 132.96, 131.23, 129.34, 128.15, 127.81, 
110.45, 104.13, 97.89, 40.09. HR ESI [M + H]+ m/z 286.1094, calc for C16H16NO4 
286.1073; HR ESI [M + Na]+ m/z 308.0915, calc. for C16H15NO4Na+ 308.0893. 
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2.4       Synthesis of 2-(8-hydroxy-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-
ij]quinoline-9-carbonyl)benzoic acid, 22.  
Phthalic anhydride (19) (0.392 g 2.64 mmol) and 8-hydroxyjulolidine (21) (0.5 g, 
2.64 mmol) are dissolved in 12 mL of toluene. The mixture is refluxed 24 h, then the 
solvent evaporated under vacuum. The target compound 22 is isolated as a pale yellow 
solid by flash column chromatography on silica gel using CH2Cl2:MeOH 95:5 for elution. 
Yield: 622 mg, 70%. 1H NMR (400 MHz, DMSO) δ 13.02 (s, 1H), 12.94 (s, 1H), 7.97 – 
7.91 (m, 1H), 7.65 (dt, J = 7.5, 3.8 Hz, 1H), 7.59 (dt, J = 7.6, 3.8 Hz, 1H), 7.33 (d, J = 6.5 
Hz, 1H), 6.39 (s, 1H), 3.24 (dd, J = 11.6, 7.0 Hz, 4H), 2.59 (t, J = 6.4 Hz, 2H), 2.41 (t, J = 
6.1 Hz, 2H), 1.90 – 1.80 (m, 2H), 1.81 – 1.70 (m, 2H). 13C NMR (101 MHz, DMSO) δ 
197.98, 167.04, 159.77, 148.79, 140.16, 131.76, 129.85, 129.66, 129.19, 127.70, 112.43, 
108.38, 104.61, 54.91, 49.39, 48.94, 26.66, 21.09, 20.09, 19.57. HR ESI [M + H]+ m/z 
338.1379, calc. for C20H20NO4 338.1386; HR ESI [M + Na]+ m/z 360.1197, calc. for 
C20H19NO4Na+ 360.1206. 
 
2.5       Synthesis of 8-methoxynaphthalen-1-ol, 24. 
Under Ar atmosphere 1,8-dihydroxynaphthalene (23) (1 g, 6.24 mmol) and ground 
K2CO3 are suspended in 5 mL of acetone, CH3I (0.88 g, 6.24 mmol) is added in one portion. 
The mixture is refluxed for 4 h.  The mixture is allowed to cool down to room temperature, 
diluted with 15 mL of DI water and then acidified to pH 1 using 6M HCl. The aqueous 
phase is extracted with ethyl acetate (2 × 50 mL). The organic extracts are combined, dried 
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over anhydrous Na2SO4, filtered and the solvent evaporated under vacuum. The target 
compound 24 is isolated by flash column chromatography on silica gel using 
EtOAc:Hexanes 25:75 for elution. Yield: 0.86 g, 79%. 1H NMR (400 MHz, DMSO) δ 9.38 
(s, 1H), 7.45 – 7.28 (m, 4H), 6.93 (dd, J = 7.6, 0.9 Hz, 1H), 6.78 (dd, J = 6.6, 2.1 Hz, 1H), 
4.02 (d, J = 5.3 Hz, 3H). 13C NMR (101 MHz, DMSO) δ 155.89, 154.00, 136.32, 127.46, 
126.17, 120.95, 118.49, 114.56, 110.05, 104.44, 56.16, 40.12.  
 
2.6       Synthesis of 8-aminonaphthalen-1-ol, 26.  
Aminonaphthalene sulfonic acid (25) (12.5 g, 56 mmol) is made into a paste with 
15 mL of water. KOH (22.3 g, 397 mmol) and NaOH (22.39 g, 560 mmol) are melted at 
200 oC in a stainless steel beaker while being stirred using a mechanical stirrer (320 rpm). 
The aminonaphthalene sulfonic acid paste is added portion wise. The temperature is 
increased slowly to 260 oC while stirred. When the temperature reaches 260 oC, the mixture 
turns dark brown, then it liquefies and the thick melt turns black giving off white fumes. 
The mixture is kept for additional 15 min at this temperature. The mixture is cooled rapidly 
to avoid further oxidation. The solidified cake is dissolved in 500 mL of DI water, and 
filtered. The filtrate is acidified with concentrated HCl to pH 1 and filtered again. The 
filtrate is neutralized by adding solid NaHCO3 portion wise. The precipitate formed is 
filtered, washed with water (300 mL) and dried under vacuum. 5.3 g (59%) of 26 are 
obtained. 1H NMR (600 MHz, DMSO) δ 7.11 – 7.03 (m, 3H), 6.86 (dd, J = 8.0, 1.1 Hz, 
1H), 6.61 (dd, J = 5.0, 3.6 Hz, 1H), 6.45 (dd, J = 7.5, 1.1 Hz, 1H). 13C NMR (101 MHz, 
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DMSO) δ 155.37, 146.33, 137.19, 126.93, 125.78, 118.89, 114.39, 113.84, 107.33, 107.22. 
HR ESI [M + H]+ m/z 160.0753, calc. for C10H10NO 160.0756. 
 
 
2.7       Synthesis of N-(8-hydroxynaphthalen-1-yl)acetamide, 28.  
8-amino-1-naphthol (26) (5 g, 31 mmol) is suspended in 100 mL of DI water. 6N 
HCl is added until a homogeneous solution is obtained, the mixture is sonicated to help to 
dissolve the solid. A yellow-black solution is obtained at pH around 1. Acetic anhydride 
(4.81 g, 47.12 mmol) is added in one portion and the mixture stirred at room temperature, 
after a few seconds a precipitate starts forming. Solid NaHCO3 is added portion wise until 
pH 6-7 is reached. A cream precipitate is obtained. The precipitate is filtered and washed 
with water and dissolved in a minimum amount of ethanol. The solution is brought to boil 
and then activated carbon is added, the mixture is boiled for additional 3 min, then filtered 
and washed with cold ethanol. DI water is added to the filtrate until a turbid solution is 
obtained, after 30 min upon standing, the target compound precipitates as small yellow 
needles. The recrystallized product is filtered, washed with water and then dried under 
vacuum. 2.05 g, (33%) of 28 are obtained. 1H NMR (400 MHz, DMSO) δ 11.23 (s, 1H), 
11.08 (s, 1H), 8.41 (d, J = 7.6 Hz, 1H), 7.49 (dd, J = 8.2, 1.0 Hz, 1H), 7.35 (ddd, J = 8.2, 
6.4, 2.8 Hz, 2H), 6.89 (dd, J = 7.4, 1.3 Hz, 1H), 2.15 (s, 3H). 13C NMR (101 MHz, DMSO) 
δ 167.67, 153.34, 136.17, 135.60, 126.29, 126.05, 122.87, 119.94, 115.10, 114.67, 110.12, 
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25.29. HR ESI [M + H]+ m/z 202.0856, calc. for C12H11NO2 202.8202; [M + Na]+ m/z 
224.0675, calc. for C12H10NO2Na 224.0675. 
 
2.8       Synthesis of 8-(dimethylamino)naphthalen-1-ol, 31.   
Under Ar atm, 1.7 M n-butyl lithium in hexanes (4.71 g, 73.6 mmol) is added in a 
continuous stream to a stirred solution of N,N-dimethyl-1-naphthylamine (29) (2.74 g, 16 
mmol) in 35 mL of anhydrous ether. The mixture is stirred 48 h at room temperature. The 
lithiated naphthylamine (30) solution is cooled down to 0 oC and 2 M n-butyl magnesium 
chloride in hexanes (7.93 g, 67.9 mmol) is added slowly in order to keep the temperature 
at 0 oC. After 20 min, the reaction mixture is cooled down to -30 oC and maintained at this 
temperature for 4 h while dry O2 is passed through the solution with stirring. A light yellow-
grey precipitate forms and the mixture cannot be longer stirred. A solution of 10% acetic 
acid in water (100 mL) is added under Ar atm, followed by the addition of Zn powder (1 
g). The two phases are stirred for 30 min until effervescence had ceased and the aqueous 
phase is neutral. The flocculated Zn is filtered and the phases separated. The organic phase 
is washed with saturated NaHCO3 solution (3 × 50 mL), water (1 × 50 mL), dried over 
anhydrous Na2SO4 and the solvent evaporated under vacuum. The target compound 31 is 
isolated by flash column chromatography on silica gel using 20% ether in hexanes, after 
pre-absorbing the crude mixture onto silica. Yield: 1.5 g, 50%. 1H NMR (400 MHz, CDCl3) 
δ 14.36 (s, 1H), 7.66 (dd, J = 8.0, 1.2 Hz, 1H), 7.41 – 7.26 (m, 4H), 6.85 (dd, J = 7.5, 1.2 
Hz, 1H), 2.84 (s, 6H).  13C NMR (101 MHz, CDCl3) δ 156.91, 150.08, 136.40, 127.75, 
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126.80, 125.69, 119.06, 118.05, 116.87, 110.05, 46.47. HR ESI [M + H]+ m/z 188.1072, 
calc. for C12H14NO 188.1069.  
 
2.9       Synthesis of 1-hydroxy-7-(2-(methoxycarbonyl)phenyl)-10H-
benzo[c]xanthen-10-iminium chloride, 3.   
Compound 17 (100 mg, 0.388 mmol) and 1,8-dihydroxynaphthalene (23) (93.4 mg, 
0.583 mmol) are dissolved in 1.5 mL of methanesulfonic acid. 1.5 mL of TFA is added and 
the mixture heated at 80 oC for 24h. The mixture is allowed to cool down to room 
temperature and then poured into 20 mL of DI water. The precipitate formed is filtered and 
washed with water until the filtrate is neutral. The title compound is isolated by flash 
column chromatography on silica gel using CH2Cl2:MeOH 95:5 for elution. 144 mg, (97%) 
of 32 are obtained.  1H NMR (600 MHz, DMSO) δ 9.86 (s, 1H), 8.05 – 7.98 (m, 1H), 7.79 
(td, J = 7.5, 1.1 Hz, 1H), 7.76 – 7.69 (m, 1H), 7.47 – 7.39 (m, 2H), 7.32 (d, J = 7.4 Hz, 
1H), 7.27 (d, J = 7.6 Hz, 1H), 7.05 – 7.00 (m, 1H), 6.63 (d, J = 2.1 Hz, 1H), 6.59 (t, J = 6.5 
Hz, 1H), 6.43 (d, J = 8.5 Hz, 1H), 6.39 (dd, J = 8.6, 2.2 Hz, 1H), 5.69 (s, 2H). 13C NMR 
(151 MHz, DMSO) δ 168.80, 154.80, 152.95, 151.39, 151.24, 148.21, 136.56, 135.55, 
130.01, 128.65, 128.18, 126.25, 124.55, 124.10, 123.87, 123.31, 118.68, 113.96, 112.20, 
111.82, 111.72, 104.67, 99.58, 84.17. HR ESI [M + H]+ m/z 382.1081, calc for C24H16NO4 
382.1073.  Compound 32 (50 mg, 131 μmol) is dissolved in 25 mL of anhydrous MeOH. 
0.750 mL of acetyl chloride is added dropwise. The mixture is stirred and heated at 50 oC 
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for 48h. 0.3 mL of acetyl chloride is added and the mixture is kept at 50 oC for additional 
24 h. The solvent is evaporated under vacuum. The title compound 3 is purified in a C18 
reversed phase SPE cartridge using MeOH:H2O 2:8, MeOH:H2O 1:1 for elution. Yield 
45.44 mg (88%). 1H NMR (400 MHz, DMSO) δ 11.47 (s, 1H), 8.91 (d, J = 15.4 Hz, 2H), 
8.34 (dd, J = 7.9, 1.0 Hz, 1H), 7.99 (td, J = 7.5, 1.3 Hz, 1H), 7.90 (td, J = 7.7, 1.3 Hz, 1H), 
7.85 – 7.77 (m, 2H), 7.61 – 7.55 (m, 2H), 7.36 (d, J = 7.2 Hz, 1H), 7.29 (d, J = 9.3 Hz, 
1H), 7.24 – 7.14 (m, 2H), 7.02 (d, J = 9.0 Hz, 1H), 3.56 (s, 3H). 13C NMR (101 MHz, 
DMSO) δ 165.09, 161.45, 160.00, 158.19, 157.57, 154.18, 138.39, 133.70, 133.59, 133.52, 
131.77, 130.97, 130.75, 130.42, 129.08, 127.17, 122.51, 121.50, 119.26, 117.47, 117.10, 
114.08, 112.28, 96.84, 52.48. HR ESI [M]+ m/z 396.1240, calc. for C25H18NO4 396.1230. 
 
 
2.10      Synthesis of 1-methoxy-7-(2-(methoxycarbonyl)phenyl)-10H-
benzo[c]xanthen-10-iminium bicarbonate, 4.  
Compound 17 (150 mg, 0.583 mmol), and compound 24 (152 mg, 0.875 mmol) are 
dissolved in 1 mL of methanesulfonic acid, then 1 mL of TFA is added. The mixture is 
stirred at 80 oC for 16h. The mixture is cooled down to room temperature and poured into 
50 mL of DI water. The mixture is neutralized to pH 6-7 by portion wise addition of solid 
NaHCO3. The precipitate formed is filtered and washed with water (25 mL), then air dried. 
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The title compound 33 is isolated by flash column chromatography using CH2Cl2:MeOH 
9:1 for elution. Yield 157 mg (68%). 1H NMR (400 MHz, DMSO) δ 8.05 – 7.99 (m, 1H), 
7.78 (dd, J = 7.5, 1.2 Hz, 1H), 7.73 (dd, J = 7.5, 1.0 Hz, 1H), 7.56 (t, J = 7.9 Hz, 1H), 7.47 
(dd, J = 13.7, 8.2 Hz, 2H), 7.29 – 7.24 (m, 1H), 7.16 (d, J = 7.2 Hz, 1H), 6.65 (d, J = 8.7 
Hz, 1H), 6.60 (d, J = 2.0 Hz, 1H), 6.40 (dt, J = 8.6, 5.3 Hz, 2H), 5.68 (s, 2H), 4.05 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 168.83, 157.04, 153.02, 151.59, 151.31, 148.04, 136.49, 
135.58, 130.04, 128.46, 128.17, 126.22, 124.58, 124.42, 124.14, 123.19, 120.30, 114.95, 
112.83, 111.72, 108.26, 104.64, 99.48, 84.29, 56.42. HR ESI [M + H]+ m/z 396.1230, calc. 
for C25H18NO4 396.1230. Compound 33 (50 mg, 126 μmol) is dissolved in 2 mL of MeOH. 
To this solution is added concentrated H2SO4 (100 μL) dropwise, then the mixture is 
refluxed for 24h. The mixture is allowed to cool down to room temperature, then poured 
into 50 mL of ice water and 200 mg of NaHCO3 is added in one portion. The precipitate 
formed is washed with 2% NaHCO3 (2 x 10 mL). The solid is transferred to a flask 
containing 50 mL of 2% HOAc. The pH of the solution is adjusted to 6-7 using 1 M NaOH. 
The aqueous phase is extracted with CHCl3 (3 x 100 mL). The organic phase is dried over 
anhydrous Na2SO4 and the solvent evaporated under vacuum to leave a dark purple solid. 
The title compound 4 is isolated by flash column chromatography on silica gel using 
CH2Cl2:MeOH 9:1 for elution. Yield 49 mg, 94%. 1H NMR (400 MHz, DMSO) δ 8.97 (d, 
J = 5.3 Hz, 2H), 8.34 (dd, J = 7.9, 1.0 Hz, 1H), 8.04 – 7.85 (m, 4H), 7.72 (d, J = 7.8 Hz, 
1H), 7.57 (dd, J = 7.6, 1.0 Hz, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.30 (d, J = 9.3 Hz, 1H), 7.24 
– 7.14 (m, 2H), 7.10 (d, J = 8.9 Hz, 1H), 4.22 (s, 3H), 3.54 (s, 3H). 13C NMR (101 MHz, 
DMSO) δ 165.07, 161.76, 160.07, 158.44, 158.33, 153.23, 138.40, 133.62, 133.54, 133.33, 
131.96, 131.00, 130.80, 130.43, 129.09, 127.03, 123.23, 121.82, 120.86, 117.96, 117.43, 
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2.11      N-(1-hydroxy-7-(2-(methoxycarbonyl)phenyl)-10H-benzo[c]xanthen-10-
yliden)-N-N-dimethyl iminium bicarbonate, 5.  
Compound 20 (0.750 g, 2.63 mmol) and 23 (0.632 g, 3.94 mmol) are dissolved in 
6.5 mL of methanesulfonic acid, then TFA (6.5 mL) are added. The mixture is heated at 80 
oC for 24h, then allowed to cool down to room temperature. The mixture is poured into 300 
mL of DI water, the purple solid is filtered and washed with water (3 × 100 mL), then dried 
under vacuum. The target compound 34 is separated by flash chromatography on silica gel 
using CHCl3:MeOH 9:1 for elution. Yield 0.778 g, 72%. 1H NMR (400 MHz, CDCl3) δ 
9.12 (s, 1H), 8.08 – 8.04 (m, 1H), 7.65 (dqd, J = 14.4, 7.3, 1.3 Hz, 2H), 7.47 (t, J = 7.9 Hz, 
1H), 7.41 (d, J = 8.8 Hz, 1H), 7.32 (dd, J = 8.1, 0.9 Hz, 1H), 7.18 – 7.15 (m, 1H), 7.08 (dd, 
J = 7.7, 1.0 Hz, 1H), 6.69 (dd, J = 8.8, 4.2 Hz, 2H), 6.55 – 6.48 (m, 2H), 3.03 (s, 6H). 13C 
NMR (101 MHz, CDCl3) δ 169.70, 154.32, 153.52, 152.23, 150.95, 148.59, 136.63, 
135.18, 129.88, 129.16, 129.00, 126.97, 125.23, 124.43, 124.11, 124.06, 119.69, 113.38, 
112.72, 112.56, 110.23, 105.84, 97.93, 83.39, 40.44. HR ESI [M + H]+ found 410.1392, 
calc. for C26H20NO4 410.1368. Compound 34 (100 mg, 243 μmol) is dissolved in 2 mL of 
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MeOH. To this solution is added concentrated H2SO4 (100 μL) dropwise, then the mixture 
is refluxed for 16 h. The mixture is allowed to cool down to room temperature, then poured 
into 50 mL of ice water and filtered. The precipitate is washed with 2% NaHCO3 (2 × 10 
mL).  The solid is transferred to a flask containing 50 mL of 2% HOAc. The pH of the 
solution is adjusted to 6-7 using 1 M NaOH. The aqueous phase is extracted with CHCl3 
(3 × 100 mL). The organic phase is dried over anhydrous Na2SO4 and the solvent 
evaporated under vacuum to leave a dark purple solid. The target compound 5 is isolated 
by flash column chromatography. A dark purple band is eluted with CHCl3:MeOH 9:1, 
8:2; yield 36 mg. A second green band was eluted with CHCl3:MeOH 1:1, then 1:3; yield 
61 mg. Total yield of 34, 97 mg, (94%). 1H NMR (400 MHz, DMSO) δ 8.32 (d, J = 7.0 
Hz, 1H), 7.97 (d, J = 7.5 Hz, 1H), 7.89 (t, J = 7.1 Hz, 1H), 7.72 (t, J = 8.6 Hz, 2H), 7.58 
(d, J = 6.7 Hz, 1H), 7.43 – 7.34 (m, 2H), 7.26 (d, J = 8.1 Hz, 1H), 7.20 (d, J = 9.6 Hz, 1H), 
7.09 (d, J = 2.4 Hz, 1H), 6.93 (d, J = 9.0 Hz, 1H), 3.54 (s, 3H), 3.39 (s, 6H). 13C NMR (101 
MHz, DMSO) δ  165.29, 158.40, 154.28, 153.85, 138.93, 135.22, 134.73, 133.24, 130.70, 
129.87, 128.79, 127.72, 124.06, 120.52, 117.48, 113.21, 96.43, 94.54, 79.25, 52.13. HR 
ESI [M+] m/z 424.1540, calc for C27H22NO4+ 424.1543. 
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2.12      N-(1-methoxy-7-(2-(methoxycarbonyl)phenyl)-10H-benzo[c]xanthen-10-
ylidene )-N-methylmethanaminium chloride, 6.  
Compound 34 (50 mg, 0.122 mmol), K2CO3 (67.5 mg, 0.488 mmol) are suspended 
in 0.6 mL of anhydrous DMF, CH3I (104 mg, 0.732 mmol) is added in one portion. The 
mixture is stirred at 60 oC for 6h, then allowed to cool down to room temperature. 2 mL of 
saturated NH4Cl are added to quench the reaction. The precipitate formed is filtered and 
washed with 0.5% NaOH (2 mL), then with water (25 mL). The title compound 6 is isolated 
by flash column chromatography on silica gel using CH2Cl2:MeOH 9:1 for elution. Yield: 
4.5 mg, (8%). 1H NMR (400 MHz, CDCl3) δ 8.36 (d, J = 7.9 Hz, 1H), 7.87 (d, J = 7.5 Hz, 
1H), 7.84 – 7.77 (m, 2H), 7.66 (d, J = 9.0 Hz, 1H), 7.61 (dd, J = 9.7, 2.0 Hz, 1H), 7.53 (d, 
J = 7.7 Hz, 1H), 7.40 (d, J = 7.5 Hz, 1H), 7.35 (d, J = 9.7 Hz, 1H), 7.24 (s, 1H), 7.13 (s, 
1H), 7.09 (d, J = 8.9 Hz, 1H), 4.30 (s, 3H), 3.63 (s, 3H), 3.59 (s, 6H). 13C NMR (101 MHz, 
CDCl3) δ 165.45, 160.65, 159.55, 159.11, 158.31, 154.73, 139.21, 134.11, 133.58, 133.39, 
131.66, 131.12, 130.89, 130.39, 129.82, 127.38, 123.24, 120.99, 119.99, 118.60, 117.63, 




2.13     Synthesis of methyl 2-(1-amino-10-oxo-10H-benzo[c]xanthen-7-yl)benzoate 7.  
Compound 15 (200 mg, 0.774 mmol), and compound 28 (234 mg, 1.16 mmol) are 
dissolved in 2.5 mL of methanesulfonic acid, then 2.5 mL of TFA are added. The mixture 
is stirred at 80 oC for 24h, then cooled down to room temperature. The mixture is poured 
into 50 mL of DI water, the precipitate obtained is filtered and washed with DI water, then 
air dried. The title compound is isolated by flash column chromatography on silica gel 
using CH2Cl2:MeOH 9:1. 33 mg of a mixed fraction containing the target product 35 is 
isolated.  17 mg of the 35 mixed fraction are dissolved in 1 mL of MeOH, 50 μL of 
concentrated sulfuric acid are added in one portion. The mixture is refluxed for 16h, the 
mixture is allowed to cool down to room temperature and poured into 10 mL of DI water. 
200 mg of NaHCO3 is added in one portion. The precipitate formed is filtered and washed 
with aqueous 2% NaHCO3, the precipitate is then suspended in 25 mL of 2% HOAc, a dark 
brown black suspension is obtained, the mixture is neutralized to pH 6-7 by adding solid 
NaHCO3 portion wise. The aqueous phase is extracted with CHCl3 (3 x 50 mL), the organic 
extracts are combined, dried over anhydrous Na2SO4, filtered and the solvent evaporated 
under vacuum to leave a black precipitate. The title compound 7 is isolated by flash column 
chromatography on silica gel using CH2Cl2:MeOH 9:1 for elution. Yield 2.7 mg, 15%. 1H 
NMR (400 MHz, CDCl3) δ 8.29 (dd, J = 7.8, 1.1 Hz, 1H), 7.78 (td, J = 7.5, 1.4 Hz, 1H), 
7.71 (td, J = 7.7, 1.4 Hz, 1H), 7.47 (t, J = 7.9 Hz, 1H), 7.41 (d, J = 8.9 Hz, 1H), 7.35 (dd, 
J = 7.5, 1.0 Hz, 1H), 7.17 (d, J = 7.7 Hz, 1H), 6.94 (d, J = 9.6 Hz, 1H), 6.86 (d, J = 7.8 Hz, 
1H), 6.82 (d, J = 8.9 Hz, 1H), 6.68 (dd, J = 9.6, 1.9 Hz, 1H), 6.63 (d, J = 1.9 Hz, 1H), 5.69 
(s, 2H), 3.63 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 185.06, 158.17, 146.15, 137.97, 
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135.26, 132.99, 131.36, 131.30, 130.72, 129.90, 129.82, 125.81, 122.57, 117.43, 112.65, 
111.41, 105.15, 52.60. HR ESI [M+ H+] m/z 396.1240, calc for C25H18NO4+ 396.1230. 
 
2.14     Synthesis of methyl 2-(1-(dimethylamino)-10-oxo-10H-benzo[c]xanthen-7-
yl)benzoate, 8.  
Compound 15 (200 mg, 0.774 mmol), compound 31 (217.5 mg, 1.16 mmol) are 
dissolved in 2.5 mL of methanesulfonic acid, then 2.5 mL of TFA is added. The mixture is 
stirred at 80 oC for 24 h, then cooled down to room temperature. The mixture is poured 
into 50 mL of DI water, the precipitate obtained is filtered and washed with DI water, then 
air dried. The crude mixture is separated by flash column chromatography on silica gel 
using CH2Cl2:MeOH 95:5 for elution; 15 mg of a mixed fraction containing 36 is isolated. 
10 mg of the 36 mixed fraction are dissolved in 1 mL of MeOH, 50 μl of concentrated 
Sulfuric acid is added in one portion. The mixture is refluxed for 16 h, the mixture is 
allowed to cool down to room temperature and poured into 10 mL of DI water. 200 mg of 
NaHCO3 are added in one portion. The precipitate formed is filtered and washed with 
aqueous 2% NaHCO3, the precipitate is then suspended in 25 mL of 2% HOAc. The 
mixture is neutralized to pH 6-7 by adding solid NaHCO3 portion wise. The aqueous phase 
is extracted with CHCl3 (3 x 50 mL), the organic extracts are combined, dried over 
anhydrous Na2SO4, filtered and the solvent evaporated under vacuum. The crude mixture 
was separated by flash column chromatography on silica gel using CH2Cl2:MeOH 9:1 for 
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elution. The isolated fraction (5.9 mg) containing the target product 8 was further separated 
by flash column chromatography on silica gel using EtOAc:MeOH 95:5 for elution.  Yield,  
1.5 mg, (14.5%). 1H NMR (400 MHz, CDCl3) δ 8.29 (dd, J = 7.8, 1.1 Hz, 1H), 7.77 (td, J 
= 7.5, 1.5 Hz, 1H), 7.70 (td, J = 7.7, 1.4 Hz, 1H), 7.56 (t, J = 7.9 Hz, 1H), 7.47 (d, J = 8.9 
Hz, 1H), 7.39 (d, J = 7.3 Hz, 1H), 7.36 (dd, J = 7.5, 1.0 Hz, 1H), 7.21 (dd, J = 7.8, 0.9 Hz, 
1H), 6.92 (dd, J = 9.1, 7.4 Hz, 2H), 6.70 (s, 2H), 3.59 (s, 3H), 3.04 (s, 6H). 13C NMR (101 
MHz, CDCl3) δ 165.77, 158.79, 152.34, 138.80, 135.39, 132.90, 131.35, 131.12, 130.80, 
130.54, 130.21, 129.80, 129.52, 125.54, 123.04, 121.50, 117.37, 116.79, 116.12, 105.25, 
52.52, 45.39. HR ESI [M+] m/z 424.1556, calc for C27H22NO4+ 424.1543. 
 
2.15     Synthesis of 1-amino-7-(2-(methoxycarbonyl)phenyl)-10H-benzo[c]xanthen-
10-iminium chloride, 9.  
Compound 17 (310 mg, 1.21 mmol), 8-aminonaphthalen-1-ol (26) (287.75 mg, 
1.81 mmol) are dissolved in 4.5 mL of methanesulfonic acid, then 4.5 mL of TFA is added. 
The mixture is stirred at 80 oC for 18 h, then cooled down to room temperature. The mixture 
is poured into 60 mL of DI water, the mixture is brought to pH 5 by portion wise addition 
of solid NaHCO3. The dark green precipitate obtained is filtered and washed with DI water. 
The title compound 37 is isolated by flash column chromatography on silica gel using 
CH2Cl2:MeOH 9:1 for elution. Yield 254.9 mg, 56%. 1H NMR (400 MHz, DMSO) δ 8.01 
(d, J = 7.6 Hz, 1H), 7.80 (td, J = 7.5, 1.1 Hz, 1H), 7.72 (td, J = 7.5, 0.7 Hz, 1H), 7.36 – 
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7.25 (m, 3H), 7.00 (d, J = 7.6 Hz, 1H), 6.82 (dd, J = 7.7, 0.7 Hz, 1H), 6.71 (d, J = 1.8 Hz, 
1H), 6.48 (d, J = 8.7 Hz, 1H), 6.43 (d, J = 2.6 Hz, 1H), 6.35 (s, 2H), 5.69 (s, 2H). 13C NMR 
(101 MHz, DMSO) δ 168.81, 152.83, 151.27, 150.99, 149.26, 146.12, 136.51, 135.56, 
130.04, 128.83, 128.31, 126.32, 124.58, 124.11, 123.88, 123.27, 115.01, 111.96, 111.69, 
110.79, 110.69, 104.78, 99.30, 84.15.  HR ESI [M + H]+ m/z 381.1232, calc. for 
C24H17N2O3 381.1233.  Compound 37 (25 mg, 66 μmol) is dissolved in 20 mL of anhydrous 
MeOH; 1.0 mL of acetyl chloride is added drop wise. The mixture is stirred and heated at 
50 oC for 48 h; 0.5 mL of acetyl chloride is added and the mixture is kept at 50 oC for 
additional 24 h. The solvent is evaporated under vacuum. The title compound 9 is isolated 
by flash column chromatography on silica gel using CH2Cl2:MeOH 90:10, 85:15, 80:20 
for elution. Yield 24 mg, 93%. 1H NMR (400 MHz, DMSO) δ 8.70 (s, 2H), 8.32 (d, J = 
6.9 Hz, 1H), 7.99 – 7.94 (m, 1H), 7.88 (dd, J = 10.9, 4.5 Hz, 1H), 7.70 – 7.63 (m, 1H), 7.55 
(dd, J = 7.6, 1.0 Hz, 1H), 7.47 (d, J = 2.0 Hz, 1H), 7.33 (s, 2H), 7.23-7.13 (m, 4H), 6.86 
(d, J = 9.0 Hz, 2H), 3.56 (s, 3H). 13C NMR (101 MHz, DMSO) δ 165.08, 160.42, 158.80, 
157.07, 156.39, 149.40, 137.94, 134.03, 133.90, 133.49, 131.31, 130.92, 130.64, 130.42, 
129.10, 127.83, 121.75, 120.61, 116.80, 115.91, 115.79, 113.85, 108.57, 97.90, 52.46. HR 
ESI [M]+ m/z 395.1386, calc. for C25H19N2O3+ 395.1390. 
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2.16     Synthesis of N-(1-amino-7-(2-(methoxycarbonyl)phenyl)-10H-
benzo[c]xanthen -10-ylidene)-N-methylmethanaminium, 10.   
Compound 20 (450 mg, 1.58 mmol), 8-aminonaphthalen-1-ol (26) (326.41 mg, 
2.05 mmol) are dissolved in 2 mL of methanesulfonic acid, then 2 mL of TFA is added. 
The mixture is stirred at 80 oC for 24 h, then cooled down to room temperature. The mixture 
is poured into 150 mL of DI water, the mixture is neutralized by portion wise addition of 
NaHCO3, the dark green precipitate obtained is filtered and washed with DI water then air 
dried. The target compound 38 is isolated by flash column chromatography on silica gel 
using CH2Cl2:MeOH 95:5, 9:1, Yield 265 mg, 41 %. 1H NMR (400 MHz, DMSO) δ 8.03 
(d, J = 7.4 Hz, 1H), 7.79 (dt, J = 7.5, 3.8 Hz, 1H), 7.73 (dt, J = 7.4, 3.7 Hz, 1H), 7.37 – 
7.24 (m, 3H), 6.98 (dd, J = 10.7, 4.6 Hz, 2H), 6.87 (d, J = 7.8 Hz, 1H), 6.59 – 6.56 (m, 2H), 
6.50 (d, J = 8.7 Hz, 1H), 6.37 (s, 2H), 2.99 (s, 6H). 13C NMR (101 MHz, DMSO) δ 168.81, 
152.93, 152.03, 151.06, 149.38, 146.16, 136.58, 135.60, 130.09, 128.85, 128.09, 126.22, 
124.63, 124.09, 123.99, 123.22, 114.82, 111.58, 110.81, 110.49, 109.99, 105.02, 98.69, 
83.96. HR ESI [M+ H+] m/z 409.15743, calc. for C26H21N2O3+ 409.15466. Under Ar, 
compound 38 (25 mg, 0.043 mmol) is dissolved in 12.5 mL of anhydrous MeOH. The 
solution is cooled down to 0 oC in an ice bath, 0.375 mL of acetyl chloride is added drop 
wise. The mixture is stirred and heated at 50 oC for 48 h; 0.2 mL of acetyl chloride is added 
and the mixture is kept at 50 oC for additional 24 h. The solvent is evaporated under 
vacuum. 27 mg (96%) of 10 are obtained. 1H NMR (400 MHz, DMSO) δ 8.33 (dd, J = 7.9, 
1.0 Hz, 1H), 7.97 (td, J = 7.5, 1.3 Hz, 1H), 7.92 – 7.85 (m, 2H), 7.68 (dd, J = 16.6, 8.6 Hz, 
2H), 7.56 (dd, J = 7.6, 1.0 Hz, 1H), 7.43 – 7.34 (m, 3H), 7.26 – 7.16 (m, 3H), 6.87 (d, J = 
9.0 Hz, 1H), 3.55 (s, 3H), 3.38 (d, J = 8.3 Hz, 6H). 13C NMR (101 MHz, DMSO) δ 165.10, 
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158.47, 157.60, 156.82, 156.39, 149.34, 137.95, 133.89, 133.52, 130.96, 130.69, 130.41, 
129.13, 127.95, 121.73, 117.08, 115.74, 115.55, 113.83, 108.24, 97.33, 52.77, 52.48. HR 
ESI [M+] m/z 423.17298, calc. for C27H23N2O3+ 423.17031. 
 
2.17     Synthesis of 15-hydroxy-9-(2-(methoxycarbonyl)phenyl)-1,2,3,5,6,7-
hexahydrobenzo [7,8] chromeno[2,3-f]pyrido[3,2,1-ij]quinolin-4-ium chloride, 11.  
Compound 22 (200 mg, 0.593 mmol), 1,8-dihydroxynaphthalene (23) (142 mg, 
0.889 mmol) are dissolved in 1.5 mL of methanesulfonic acid, then 1.5 mL of TFA is 
added. The mixture is stirred at 80 oC for 24 h, then cooled down to room temperature. The 
mixture is poured into 50 mL of DI water, the precipitate obtained is filtered and washed 
with DI water then dried under vacuum. 256 mg (93%) of 39 are obtained. 1H NMR (400 
MHz, DMSO) δ 11.39 (s, 1H), 8.27 (d, J = 7.7 Hz, 1H), 7.90 (t, J = 7.3 Hz, 1H), 7.83 (t, J 
= 7.5 Hz, 1H), 7.70 (dd, J = 17.0, 8.5 Hz, 2H), 7.48 (t, J = 7.3 Hz, 2H), 7.24 (d, J = 7.8 Hz, 
1H), 6.92 (d, J = 8.9 Hz, 1H), 6.85 (s, 1H), 3.63 (d, J = 22.7 Hz, 6H), 2.76 (s, 2H), 2.06 (s, 
2H), 1.91 (s, 2H). 13C NMR (101 MHz, DMSO) δ 166.46, 158.01, 157.68, 156.84, 137.90, 
133.16, 130.38, 126.35, 125.32, 122.66, 119.13, 118.37, 115.38, 113.42, 112.67, 105.31, 
50.94, 50.64, 26.89, 19.77, 18.86. HR ESI [M+ H+] m/z 462.1690, calc. for C30H24NO4+ 
462.17108. Compound 39 (50 mg, 0.108 mmol) is dissolved in 25 mL of anhydrous MeOH. 
0.75 mL of acetyl chloride is added drop wise. The mixture is stirred and heated at 50 oC 
for 48 h. 0.3 mL of acetyl chloride is added and the mixture is kept at 50 oC for additional 
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24 h. The solvent is evaporated under vacuum, the target compound 11 is isolated by flash 
column chromatography on silica gel using CH2Cl2:MeOH 90:10 for elution. Yield 46 mg, 
90%. 1H NMR (400 MHz, DMSO) δ 11.50 (s, 1H), 8.33 (d, J = 7.8 Hz, 1H), 7.97 (t, J = 
7.3 Hz, 1H), 7.92 – 7.85 (m, 1H), 7.73 (dd, J = 12.5, 8.5 Hz, 2H), 7.53 (t, J = 7.9 Hz, 2H), 
7.31 (d, J = 7.9 Hz, 1H), 6.95 – 6.87 (m, 2H), 3.71 (s, 2H), 3.65 (s, 2H), 3.56 (s, 3H), 3.33 
(s, 2H), 2.78 (s, 2H), 2.08 (s, 2H), 1.92 (s, 2H). 13C NMR (101 MHz, DMSO) δ 201.26, 
164.65, 157.10, 156.33, 152.34, 130.52, 129.06, 116.89, 113.67, 113.39, 112.24, 105.24, 
103.61, 52.59, 50.51, 19.55, 18.60. HR ESI [M]+ m/z 476.1858, calc. for C31H26NO4+ 
476.1856. 
 
2.18     Synthesis of 15-methoxy-9-(2-(methoxycarbonyl)phenyl)-1,2,3,5,6,7-
hexahydrobenzo[7,8]chromeno[2,3-f]pyrido[3,2,1-ij]quinolin-4-ium chloride, 12.  
Under Ar atm, compound 39 (25 mg, 0.054 mmol) is dissolved in 0.5 mL of 
anhydrous DMF, to this solution is added K2CO3 (22.5 mg, 0.162 mmol) and CH3I (31 mg, 
0.217 mmol). The mixture is heated at 60 oC for 24 h, then allowed to cool down to room 
temperature. 2 mL of saturated NH4Cl is added to quench the reaction. The precipitate 
formed is filtered and washed with 0.5% NaOH (2 mL), then with water (25 mL). The title 
compound 12 is isolated by flash column chromatography on silica gel using 
CH2Cl2:MeOH 90:10 for elution. Yield: 16 mg, 59%. 1H NMR (400 MHz, CDCl3) δ 8.36 
(dd, J = 7.9, 1.1 Hz, 1H), 7.91 – 7.84 (m, 1H), 7.82 – 7.72 (m, 2H), 7.60 (d, J = 8.9 Hz, 
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1H), 7.50 (d, J = 7.9 Hz, 1H), 7.39 (d, J = 6.7 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 7.01 (d, J 
= 8.9 Hz, 1H), 6.78 (s, 1H), 4.22 (s, 3H), 4.05 – 3.89 (m, 2H), 3.84 – 3.69 (m, 2H), 3.64 (s, 
3H), 3.38 (dd, J = 12.8, 7.2 Hz, 2H), 2.95 – 2.74 (m, 2H), 2.39 – 2.01 (m, 4H). 13C NMR 
(101 MHz, CDCl3) δ 165.59, 158.81, 156.53, 154.52, 153.32, 138.73, 134.59, 133.58, 
132.36, 131.54, 130.76, 130.56, 129.86, 129.77, 126.66, 125.79, 123.21, 120.99, 118.11, 
117.86, 114.58, 108.74, 106.16, 56.79, 52.74, 52.32, 52.05, 28.08, 20.40, 20.18, 19.65. HR 
ESI [M]+ m/z 490.2026, calc. for C32H28NO4+ 490.2012. 
 
2.19     Synthesis of 15-amino-9-(2-(methoxycarbonyl)phenyl)-1,2,3,5,6,7-
hexahydrobenzo[7,8]chromeno[2,3-f]pyrido[3,2,1-ij]quinolin-4-ium chloride, 13.  
Compound 22 (100 mg, 0.296 mmol) and compound 26 (71 mg, 0.444 mmol) are 
dissolved in 1.5 mL of methanesulfonic acid, then 1.5 mL of TFA is added. The mixture is 
stirred at 80 oC for 24 h, then cooled down to room temperature. The mixture is poured 
into 50 mL of DI water, then neutralized by portion wise addition of NaHCO3, the green 
precipitate obtained is filtered and washed with DI water then air dried. The target 
compound is isolated by flash column chromatography on silica gel using CH2Cl2:MeOH 
90:10, 80:20, and then 100% MeOH to elute the last dark green band that corresponds to 
the target compound 40. The MeOH fraction is evaporated under vacuum, and the resulting 
solid is dissolved in a mixture of CH2Cl2
to remove any dissolved silica. Yield 52 mg, 39 %. 1H NMR (400 MHz, DMSO) δ 8.01 (d, 
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J = 7.4 Hz, 1H), 7.79 (td, J = 7.5, 1.2 Hz, 1H), 7.72 (td, J = 7.5, 0.9 Hz, 1H), 7.37 – 7.25 
(m, 3H), 7.01 (d, J = 7.3 Hz, 1H), 6.81 (d, J = 6.7 Hz, 1H), 6.47 (d, J = 8.7 Hz, 1H), 6.38 
(s, 2H), 6.13 (s, 1H), 3.23 – 3.10 (m, 2H), 2.98 (d, J = 5.0 Hz, 1H), 2.02 (d, J = 2.9 Hz, 
2H), 1.85 – 1.75 (m, 2H). 13C NMR (101 MHz, DMSO) δ 168.83, 153.34, 152.90, 149.78, 
149.33, 147.24, 146.83, 145.90, 145.24, 144.55, 136.55, 135.57, 130.04, 128.76, 126.35, 
124.61, 124.19, 123.96, 123.31, 118.66, 115.22, 115.01, 112.06, 110.74, 110.65, 108.55, 
106.10, 104.40, 84.50, 63.19, 49.20, 48.32, 26.76, 21.64, 21.13, 20.73, 18.57. HR ESI [M+ 
H]+ m/z 461.1869, calc. for C30H25N2O3+ 461.1859. Compound 40 (20 mg, 0.043 mmol) is 
dissolved in 15 mL of anhydrous MeOH; 0.75 mL of acetyl chloride is added drop wise. 
The mixture is stirred and heated at 50 oC for 48 h; then 0.2 mL of acetyl chloride is added 
and the mixture is kept at 50 oC for additional 24 h. The solvent is evaporated under 
vacuum. 21 mg (100%) of the target compound 13 are obtained. 1H NMR (400 MHz, 
DMSO) δ 8.32 (dd, J = 7.9, 1.0 Hz, 1H), 7.96 (td, J = 7.5, 1.3 Hz, 1H), 7.92 – 7.84 (m, 
1H), 7.69 – 7.63 (m, 2H), 7.50 (d, J = 6.6 Hz, 1H), 7.30 (d, J = 7.6 Hz, 1H), 7.22 (d, J = 
7.9 Hz, 1H), 6.90 – 6.79 (m, 2H), 3.73 – 3.61 (m, 4H), 3.57 (s, 1H), 3.27 (d, J = 5.9 Hz, 
2H), 2.82 – 2.74 (m, 2H), 2.10 (dd, J = 12.5, 6.5 Hz, 2H), 1.91 (s, 2H).  13C NMR (101 
MHz, CDCl3) δ 165.57, 156.75, 156.60, 153.20, 152.80, 148.90, 138.31, 134.80, 133.87, 
133.38, 131.49, 130.59, 130.39, 129.97, 128.08, 127.94, 125.73, 121.57, 117.28, 116.96, 
116.34, 114.91, 110.34, 106.08, 54.50, 52.75, 51.76, 51.26, 28.00, 21.21, 20.38, 19.56.. 




CHAPTER 3.  SPECTRAL PROPERTIES  
 
The spectral properties of this series of probes (1-13) based upon 
seminaphthofluorescein, seminaphthorhodafluor, and seminaphthorhodamine scaffolds 
were screened for pH and solvent dependence. Absorption and fluorescence spectra of 
compounds containing ionizable hydroxyl groups (seminaphthofluorescein 1, and 
seminaphthorhodafluors 3, 5 and 11) exhibited pH dependence over the physiological 
range as well as sensitivity to solvent composition. In aqueous solution, the hydroxyl forms 
of 1, 3, 5 and 11 were red-emitting while their conjugate bases exhibited near-infrared 
(NIR) fluorescence. Solvent dependence is at least partially attributable to differences in 
tautomer equilibria of the compounds in the various solvents. The observed pH and solvent 
sensitivity was removed through derivatization. Methoxy-functionalized analogs (2, 4, 6 
and 12) displayed relatively bright red fluorescence and were independent of variations in 
pH and solvent composition. Replacing the hydroxyl with amines generated a series of 
NIR-emitting seminaphthorhodamines (9, 10 and 13). The spectral properties of 9, 10 and 
13 were pH independent and only modestly dependent on solvent. Transposition of thy 
hydroxyl and amine functionalities in seminathorhodafluors 3 and 5 generated compounds 
7 and 8. Transposition lowered the pKa resulting in spectral properties that were not pH 
dependent in the physiological range.  
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3.1       pH-dependent Spectral Properties of Dual-emitting Seminaphthofluorescein 
and Seminaphthorhodafluors. 
 
Figure 3.1 Absorption spectra (solid lines) and normalized fluorescence emission 
spectra (dash lines) of pH-dependent 1, 3, 5 and 11 in acidic solution (pH 1.9, HCl). 
Red emitting species were excited at 480 nm or 510 nm. Emission spectra are normalized 
to their their corresponding absorption peaks. 
 
Figure 3.2 Excitation Emission Matrices, of pH-dependent 1 (a), 3 (b), 5 (c) and 11 (d) 
in acidic solution. The color scale of EEMs are normalized to the maximum of each plot. 
The spectral properties of compounds 1, 3, 5, and 11 are pH sensitive as a result of 






























of the compounds display structured absorption peaks with maxima ranging from 530 to 
585 nm, modest Stokes shifts, and fluorescence emission maxima between 600 and 624 
nm.  
Table 3.1   Tabulated spectral properties of pH-dependent 1, 3, 5 and 11 in acidic 
solution. 
Compound 
λmax abs  
(Extinction Coefficient) 







1 530 (12,167) 600 (1.17) 70 142 7.72 +/- 0.04 
3 542 (19,787) 604 (1.14) 62 226 6.67 +/- 0.11 
5 567 (20,399) 614 (4.09) 47 834 6.82 +/- 0.06 
11 585 (15,134) 624 (15.3) 39 2314 7.84 +/- 0.11 
 
 
Figure 3.3  Absorption spectra (solid lines) and normalized fluorescence emission 
spectra (dash lines) of pH-dependent 1, 3, 5 and 11 in basic solution (pH 12.1, NaOH). 
NIR emitting species in were excited at 630 nm. Emission spectra are normalized to their 
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Figure 3.4   Excitation Emission Matrices, of pH-dependent 1 (a), 3 (b), 5 (c) and 11 
(d) in basic solution. The color scale of EEMs are normalized to the maximum of each 
plot. 
Table 3.2   Tabulated spectral properties of pH-dependent 1, 3, 5 and 11 in basic 
solution. 
Conjugate base of 
λmax abs  
(Extinction Coefficient) 







1 599 (8,613) 760 (0.19) 161 16 
3 621 (15,589) 770 (0.11) 149 17 
5 632 (17,252) 780 (0.17) 148 29 
11 643 (14,454) 770 (0.30) 127 43 
The conjugate bases of these compounds display broad featureless absorption peaks 
ranging from 599-643 nm, large Stokes shifts, and broad fluorescence emission peaks in 
the NIR. Quantum yields of the NIR emitting species were generally ~3-5 times higher in 





Figure 3.5 Absorption spectra as a function of pH for pH-dependent 1 (a), 3 (b), 5 (c) 




































































































Figure 3.6 Absorption spectra of 1, 3, 5 and 11 as a function of solvents including 











































































Ratiometric absorption spectra with pKa values in the physiological range were 
observed for 1, 3, 5 and 11. Well defined isosbestic points indicate spectral changes result 
from acid-base equilibria between two species. In aqueous solution at low pH, a single 
tautomer with hydroxyls on the annulated ring dominate. Absorptions from both tautomers 
are apparent in organic solvents. Long wavelength tautomers are more pronounced in 3 
and 5 as compared to 1 and 11; and in DMSO as compared to MeOH. Methyl ether 
derivatives 2, 4, 6 and 12 approximate naphthol tautomers, existing as single species 
similar to short wavelength tautomers of 1, 3, 5, and 11 in organic solvents. 
 
3.2    pH-independent Spectral Properties of Red-emitting Methyl Ether Derivatives.  
 
Figure 3.7 Absorption spectra (solid lines) and normalized fluorescence emission 
spectra (dash lines) of pH-independent 2, 4, 6 and 12 in pH 7.4 buffer. Red emitting 
species were excited at 480 nm or 510 nm. Emission spectra are normalized to their 
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Figure 3.8   Excitation Emission Matrices of pH-independent 2 (a), 4 (b), 6 (c) and 12 
(d) in pH 7.4 buffer. The color scale of EEMs are normalized to the maximum of each 
plot. 
 
Table 3.3   Tabulated spectral properties of pH-independent 2, 4, 6 and 12 in basic 
solution. 
Compound 
λmax abs  
(Extinction Coefficient) 







2 530 (15,610) 580 (46.49) 50 7257 
4 538 (21,742) 596 (34.42) 58 7484 
6 568 (22,470) 606 (9.32) 38 2094 









Figure 3.9  Absorption spectra as a function of pH for methyl ether derivatives 2 (a), 






































































































Figure 3.10  Absorption spectra as a function of solvents including DMSO, MeOH 



































































































3.3    pH-independent Spectral Properties of NIR-emitting Seminaphthorhodamines.  
 
 
Figure 3.11  Absorption spectra (solid lines) and normalized fluorescence emission 
spectra (dash lines) of pH-independent 9, 10 and 13 in pH 7.4 buffer. NIR emitting 




Figure 3.12  Excitation Emission Matrices of pH-independent 9 (a), 10 (b), and 13 (c) 




























Table 3.3   Tabulated spectral properties of pH-independent 2, 4, 6 and 12 in basic 
solution. 
 Compound 
λmax abs  
(Extinction Coefficient) 







9 576 (13,872) 760 (0.18) 184 25 
10 598 (17,066) 770 (0.20) 172 34 
13 601 (12,808) 740 (0.66) 139 85 
 
Replacing the ionizable hydyroxyl groups with a methyl ether (compounds 2, 4, 6, 
12) removes both the pH and tautomeric equilibria of compounds 1, 3, 5, 11, thus 
approximating naphthol tautomers in a range of solvents and pH values. Absorption spectra 
of the methyl ether derivatives are nearly identical to their corresponding hydroxyl analogs. 
Emission wavelengths of the methyl ethers remain in the orange/red region. Quantum 
yields of the methyl ethers range from ~10-45% and are generally improved as compared 
to their hydroxyl analogs (improvements of ~40 fold for 2, 30 fold for 4 and more than 2 
fold for 6). No pH or tautomeric equilibria are observed for the methyl ether derivatives. 
There was no significant change in wavelength upon changing solvents from DMSO to 




Figure 3.13  Absorption spectra as a function of pH-independent 












































































Figure 3.14  Absorption spectra as a function of solvents including DMSO, MeOH 
and pH 7.4 phosphate buffer for pH-independent seminaphthorhodamines 9 (a), 10 
(b) and 13 (c). 
 
Replacing the hydroxyl group with an NH2 group (compounds 9, 10 and 13) 












































































wavelength NIR emission observed in the conjugate bases of compounds 3, 5, and 11 in a 
range of pH values for the resulting seminaphthorhodamines. The seminaphthorhodamines 
show no sensitivity to pH over a wide range encompassing physiological pH. Emission 
maxima are all greater than 740 nm with large Stokes shifts. The seminaphthorhodamines 
are approximately twice as bright as the corresponding long wavelength emissions 
observed for the conjugate bases of compounds 3, 5 and 11. Quantum yields of the NIR 
emitting species were generally ~3-5 times higher in the organic solvents MeOH and 
DMSO as compared to aqueous solution. No pH equilibria are observed for the 
seminaphthorhodamine derivatives. Seminaphthorhodamines 9, 10 and 13 display 
moderate sensitivity to polarity with the longest wavelengths in DMSO and the shortest in 
aqueous solution.  
3.4       pH-dependent Spectral Poperties of Tansposed Sminaphthorhodafluors 
 
 
Figure 3.15  Absorption spectra (solid lines) and normalized fluorescence emission 
spectra (dash lines) of conjugate acids of 7 and 8 in acidic solution (pH 1.9, HCl). Red 
emitting species were excited at 480 nm, and NIR emitting species were excited at 630 nm. 



























7, λex = 630 nm




Figure 3.16  Excitation Emission Matrices of conjugate acids of 7 (a), and 8 (b) in 
acidic solution (pH 1.9, HCl). The color scale of EEMs are normalized to the maximum 
of each plot. 
 
Table 3.5 Tabulated spectral properties of the conjugate acids of 7 and 8 in acidic 
solution. 
Conjugate acid of 
λmax abs  
(Extinction Coefficient) 






7 598 (3,996) 770 172 4.99 +/- 0.13 





Figure 3.17  Absorption spectra (solid lines) and normalized fluorescence emission 
spectra (dash lines) of 7 and 8 in basic solution (pH 12.1, NaOH). Red emitting species 
were excited at 480 nm, and NIR emitting species were excited at 630 nm. Emission spectra 
are normalized to their corresponding absorption peaks. 
 
 
Figure 3.18   Excitation Emission Matrices of 7 (a), and 8 (b) in basic solution (pH 





























7, λex = 480 nm
7, λex = 630 nm






Table 3.6  Tabulated spectral properties of 7 and 8 in basic solution. 
Compound 
λmax abs  
(Extinction Coefficient) 





7 509 (8,300) 530 21 
7 549 (5,664) 750 201 
8 530 (8,834) 530 21 
 
Compared to seminaphthorhodafluors 3 and 5, the hydroxyl and amine groups are 
transposed in compounds 7 and 8.  Seminaphthorhodafluors 3 and 5 were isolated as acidic 
salts with pKa values in the physiological range, resulting in ratiometric spectral properties 
(short wavelength absorption and emission for the acids with long wavelength absorption 
and emission for the conjugate bases).  The transposed compounds were isolated as neutral 
species, having pKa values approximately 2 units lower, thus displaying no sensitively to 
pH over the physiological range. At physiological pH and in organic solvents, both 7 and 
8 displayed an absorption maxima near 525 nm. Protonation lead to a long wavelength 
absorption near 600 nm for 7 and short wavelength absorption near 450 nm for 8. 
Compound 8 was short wavelength absorbing and emitting as both the base and conjugate 
acid with no long wavelength species observed. Interestingly, 7 displayed dual emission as 
both the base and conjugate acid.  These dual emissions are attributed to different 
tautomeric forms exhibiting less strained geometries. 
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CHAPTER 4.  PROBE IN VITRO STUDIES 
 
4.1 Structures and Calculated Physicochemical Properties Summary of 2, 12 and 13. 
Compounds 2, 12 and 13 are representative of three classes of benzo[c]xanthenes 
and were chosen as candidates for initial in vitro and in vivo screening for pancreas and 
PDAC targeting based on their predicted physiochemical properties, pH independence, and 
attractive spectral properties.  
 
Figure 4.1  Structures and calculated physicochemical properties summary of 2, 12 
and 13. 
These dyes (Fig.4.1) represent three classes of benzo[c]xanthenes: 
seminaphthofluorescein (2), seminaphthorhodafluor (12), and seminaphthorhodamine 
(13). Color-mapped surfaces show the molecular electrostatic potential (blue is positive, 




MW = 410.42 g/mol
Log D = 4.49
Formal charge = 0
H-bond donors = 0
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Log D = 1.91
Formal charge = +1
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H-bond acceptors = 4
Polar surface area = 47.77 Å2
Dipole moment = 6.52 Debye
MW = 475.56 g/mol
Log D = 1.24
Formal charge = +1
H-bond donors = 2
H-bond acceptors = 4
Polar surface area = 64.56 Å2






reveals potential biological activity differences in response to structural variations in the 
molecular design. 
 
4.2       In Vitro Cell Viability of Compounds 2, 12 and 13. 
 
Figure 4.2   Cell viability of compounds 2, 12, and 13 in Capan-1 cells. 
 
In vitro cell viability (Fig. 4.2) was assessed in the presence of compounds 2, 12 
and 13 in Capan-1 cells, a representative PDAC cell line. The cytotoxicity studies 
demonstrated that compound 2 was the least toxic (IC50 30.08 μM) followed by compounds 

























4.3         In Vitro Time-dependent Fluorophore Uptake of Compounds 2, 12 and 13.  
 
Figure 4.3   Cellular uptake of compounds 2, 12, and 13 in Capan-1 cells. 
 
In vitro time-dependent fluorophore uptake was investigated in PDAC cells (Fig. 
4.3). Each fluorophore exhibited similar kinetics, demonstrating uptake within 30 min of 
fluorophore application.  Compound 13 exhibited the greatest uptake, and 2 the lowest 
during this period. We attribute this to the favorable membrane interactions of the cationic 
fluorophores 12 and 13 as compared to neutral 2. After 30 min, all compounds showed a 
relatively slow increase in uptake that lasted for up to 2 h. Compounds 12 and 13 began 
clearing from the cells after 2 h.  
 


























4.4       Subcellular Localization of Compounds 2, 12, and 13. 
 
Figure 4.4  Subcellular localization of compounds 2 in Capan-1 cells. Fluorescence 
images containing synthesized fluorophores are labeled as 2 (red). Images of 
subcellular organelles stained with commercial fluorescent trackers are labeled as DAPI 
(blue), ER (green) or Mito (green). The merge columns show images of (top) phase contrast 
of compound 2, followed successively below by colocalization of DAPI + compound 2, 











Figure 4.5  Subcellular localization of compounds 12 in Capan-1 cells. Fluorescence 
images containing synthesized fluorophores are labeled as 12 (red). Images of 
subcellular organelles stained with commercial fluorescent trackers are labeled as DAPI 
(blue), ER (green) or Mito (green). The merge columns show images of (top) phase contrast 
of compound 12, followed successively below by colocalization of DAPI + compound 12, 










Figure 4.6  Subcellular localization of compounds 13 in Capan-1 cells. Fluorescence 
images containing synthesized fluorophores are labeled as 13 (red). Images of 
subcellular organelles stained with commercial fluorescent trackers are labeled as DAPI 
(blue), ER (green) or Mito (green). The merge columns show images of (top) phase contrast 
of compound 13, followed successively below by colocalization of DAPI + compound 13, 










The subcellular localization of 2, 12 and 13 was investigated in Capan-1 cells after 
1 h incubation. Organelle-specific fluorescent probes were used to assess the site-specific 
uptake of each fluorophore. The preferential intracellular localization of compound 2 was 
within vesicular structures that may embody lipid droplets, endosomes, or other membrane-
based vesicles. In contrast to 2, compounds 12 and 13 demonstrated more homogeneous 
distribution across cells with extensive accumulation in the mitochondria (Mito) as well as 
limited accumulation in the nucleus and endoplasmic reticulum (ER). As 12 and 13 are 
cationic, they distribute electrophoretically in the mitochondrial matrix in response to the 









CHAPTER 5. PROBE IN VIVO BIODISTRIBUTION STUDIES 
 
The initial biodistribution profile screening of 2, 12, and 13 was carried out in 
healthy CD-1 mice and compared to MB to assess their pancreas specificity. Compounds 
2, 12, 13 (100 nmol) or MB (120 nmol) were injected intravenously (n = 3 mice per 
compound). Fluorescence images were collected prior to fluorophore administration 
enabling each animal to act as its own control and at 0, 5, 15, 30, 60 min for each of 2, 12, 
13 and MB, and additionally at 2 h and 4 h for compounds 2, 12 and 13. A series of 
representative intraoperative fluorescence images taken over time, as well as a resected 
organ SBR comparison of the dyes, are shown in Fig. 5.1-5.3.  
 
Figure 5.1 Representative real time intraoperative fluorescence imaging of compound 
2, 12, 13 and MB. 







































































































Despite their structural similarities, the in vivo biodistribution of each of 2, 12 and 
13 was distinct as assessed by intraoperative imaging throughout the 4 h distribution phase 
(Fig. 5.1). Compound 2 preferentially accumulated mainly in the pancreas, intestine and 
bladder, demonstrating significant hepatic clearance. Compound 12 accumulated in the 
kidney, pancreas, and intestine, demonstrating both renal and hepatic clearance. Compound 
13 accumulated largely in the kidneys, with significant clearance from the other assessed 
organs 4 h after systemic administration demonstrating renal clearance. 
Although all three probes accumulated in the kidney and liver soon after 
administration, their preferable clearance routes and rates from these organs differed with 
respect to renal vs. hepatic clearance. The smallest fluorophore, 2, exhibited the highest 
bladder fluorescence and faster renal clearance than compounds 12 and 13. Compounds 12 
and 13 cleared more slowly than 2 and were retained in the kidney for relatively longer 
periods. Compound 12 exhibited a greater hepatic excretion rate as compared to 
compounds 2 and 13. The accumulation profiles of compounds 2 and 13 in the intestine 
were similar, even though compound 2 was more lipophilic and less water soluble 
compared to compound 13. The overall profiles in other quantified tissues including 




Figure 5.2  In vivo organ biodistribution kinetics of synthesized compounds vs. 
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following systemic administration of (a) compound 2, (b) compound 12, (c) compound 13, 
or (d) MB. Mean fluorescence intensities were calculated for n = 3 injected mice per 
compound. Fluorescence intensities for each organ were normalized to muscle 
fluorescence intensity per animal per time point. Data is presented as the mean ± S.D. 
 
Figure 5.3 Ex vivo resected organ normalized fluorescence intensity comparison of 
compounds 2, 12 and 13. 
Compound 12 exhibited the highest and most persistent fluorescence SBR in the 
pancreas as compared to surrounding organs at the 4-h time point. It had 4-fold higher 
uptake in normal pancreas tissue as compared to previously studied MB (log D = -0.62). 
MB extravasated to some degree but demonstrated poor penetration into normal pancreas 
tissue (Fig. 5.1-5.2). The low in vivo efficacy of MB could be attributed to its relatively 
low lipophilicity and high water solubility, as it is preferentially and rapidly cleared 
through the renal system after systemic administration. MB’s low tissue fluorescence, rapid 
clearance rate and reduced bioavailability limited its pancreas tissue selectivity and thus its 
potential for image-guided surgery applications. From the study herein, higher log D value 
compounds 2 and 12 exhibited improved pancreas specificity whereas 13 and MB had 
















































































biodistribution and tissue permeability28,32 of more members of the benzo[c]xanthene and 
related dye series will further validate these and related trends, and is ongoing.  
  
 58 
CHAPTER 6.  GENETICALLY ENGINEERED MOUSE MODELS OF PDAC 
IMAGING 
 
Genetically engineered mouse models of PDAC tumors that recapitulate the 
clinical, pathological and genomic features of human PDAC33-35 were used to assess the 
specificity of the fluorophores for PDAC accumulation. Compound 12 afforded the highest 
pancreas tissue uptake in healthy mice and was chosen for study in the genetically modified 
PDAC tumor-bearing mouse model.  
 
Figure 6.1 Ex vivo microscopy images of control and PDAC tissue slides stained with 
compound 12. Microscopy images of compound 12 stained pancreas tissue slides showing 
representative large, medium duct type adenocarcinoma tissue and acinar cells resected 
from PDAC tumor bearing mice compared with the one resected from a healthy mouse 
pancreas (left).  
 
Ex vivo staining of pancreas tissue derived from healthy and PDAC mice showed 
that their characteristic features were highlighted by 12 (Fig. 6.1). The healthy mouse 
pancreas tissue showed uptake of 12 in its abundant acinar cell population. In contrast, in 
the cancerous tissue, 12 localized in the PDAC-associated ductal epithelial cells, enabling 
them to be observed via an increased fluorescence signal that was visually brighter 
Control Acinar Medium Ductal Large Ductal
PDAC tissue
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compared to that of the acinar cells in healthy tissue. Thus, 12 enabled ex vivo staining to 
distinguish the features of healthy and PDAC tissue.  
 
Figure 6.2  Real time intraoperative fluorescence imaging of PDAC tumor bearing 
mice injected with compound 12. a, the location of the pancreas in the peritoneal cavity 
is shown outlined in yellow, with (top) and without (bottom) compound 12 administration. 
In the images, the pancreas is observed only after injection of 12. b, Macroscopic images 
of resected pancreas tissue from PDAC tumor bearing mice ex vivo either following 
systemic administration of compound 12 (top) or from an uninjected PDAC tumor bearing 
mouse (bottom) confirming the lack of pancreas fluorescence without 12. The images of 
mice injected with 12 are representative of data collected for n = 5 injected PDAC mice. 
All fluorescence images were collected at 50 ms exposure time. Images are displayed with 
equal normalization between compound 12 and the uninjected control. Imaging results 
demonstrates morphology and tissue uptake differences between the healthy mice and 
PDAC tumor bearing mice, as well as the fluorescence resulting from 12 versus 
autofluorescence. 
 
Compound 12 was systemically administered to n = 5 genetically modified PDAC 
mice. Pancreas specific fluorescence was monitored over 1.5 h. Significantly more 
fluorescence was seen in compound 12 injected PDAC bearing animals compared to 
uninjected control PDAC bearing animals. After euthanasia, the pancreas was assessed 





































intraoperative fluorescence images over time as well as the in vivo organ biodistribution 
kinetics of compound 12 are shown in Fig. 6.3.  
 
Figure 6.3 Biodistribution of compound 12 in PDAC mice. a, Representative images of 
the fluorescence intensity in the peritoneal cavity over time following systemic 
administration of compound 12 in PDAC tumor bearing mice; b, corresponding mean 
fluorescence intensities measured for each organ. All images are representative of data 
collected for n = 5 systemically administered mice. All fluorescence images were collected 
at 50 ms exposure time. All images are displayed with equivalent normalization between 
time points. Quantified fluorescence intensity for each organ was normalized to the muscle 
intensity per animal per time point. Data is presented as the mean ± S.D. In = Intestine; Li 
= liver; Pa = pancreas; Sp = spleen; St = stomach; Bl = Bladder; Ki = Kidney.  
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Figure 6.4 Ex vivo pathology of resected PDAC tissue. Microscopy images of H&E, 
pan-cytokeratin and compound 12 stained slides showing representative (a) small, (b) 
medium, and (c) large duct type adenocarcinoma tissue as well as (d) acinar cells resected 
from PDAC tumor bearing mice injected with 12. Pan-cytokeratin antibody staining 
H&E
Immuno






































































highlights PDAC cells. Comparison to the fluorescence images obtained with 12 to those 
obtained with the antibody confirms their similar PDAC staining patterns.  
 
Figure 6.5 Ex vivo pathology of resected PDAC tissue from uninjected control mice. 
Representative microscopy images of (a) medium and (b) large duct type adenocarcinoma 
tissue and of (c) normal pancreatic acinar cells next to small duct type adenocarcinoma 
tissue resected from uninjected PDAC tumor bearing mice. Control IF images were 
collected from serial sections that had been stained using the same procedure as those for 























































H&E IF - Control AutofluorescenceCytokeratin
 63 
specificity. Images were collected in the compound 12 fluorescence channel and were 
normalized to compound 12 fluorescence images in Fig. 6.4 for each respective tissue type 
to demonstrate autofluorescence in the compound 12 fluorescence channel in unstained 
PDAC tissue.  
Representative serially sectioned tissues stained with pan-cytokeratin to assess 
PDAC specificity of compound 12 confirmed that accumulation of compound 12 in PDAC 
tumor tissue was significantly higher than in the surrounding tissues and specific for the 
malignant cells (Fig. 6.4). Hematoxylin and Eosin (H&E) staining of the PDAC specimens 
revealed that uptake of 12 occurred in ductal tissue epithelial cells. This is consistent with 
the fact that pancreatic ductal epithelial cells give rise to PDAC.36 Furthermore, the 
accumulation of 12 in PDAC mouse acinar cells (Fig. 6.4d) also demonstrated co-
localization with the pan-cytokeratin immunofluorescence staining. This is apparently in 
keeping with studies that have shown that genetic mutations of acinar cells are associated 




CHAPTER 7.   SUMMARY AND OUTLOOK 
 
Early detection and improved treatment options have increased the survival rate of 
many prevalent cancers such as those of the breast, colon, and prostate. However, to date 
surgical resection offers the only chance for a cure for PDAC due to relatively late 
detection. Cancer cure is directly related to the margin status of the resected tumor;42,43  
however, complete resection with negative margins remains a major challenge.6,44 This 
leaves many patients with residual disease, leading to early cancer recurrence following 
what was thought to be a potentially curative operation.45  The utilization of engineered 
antibodies has been assessed for identifying margin status, as they can enable targeting of 
imaging probes to cancer cells in vivo.46,47  However, antibody imaging probes have 
relatively long retention times in non-targeted tissues and slow clearance from circulation 
as compared to small molecule fluorophores. Furthermore, due to poor cell-membrane 
permeability, antibody-based imaging is limited in its applications to cell-surface 
biomarkers.48   
During the past few years, a limited number of small molecule fluorescent probes 
for PDAC have been reported that are conjugated to targeting moieties smaller than 
antibodies.49-54 Like their antibody counterparts, they were designed to target specific 
proteins (e.g., cathepsins, matrix metalloproteinases, claudin-4 or integrin integrin v3) 
that are overexpressed in PDAC as well as other cancers. All probes of this type require 
conjugation to a peptide or peptidomimetic, where the biodistribution of the conjugated 
probe will be dependent upon both the targeting sequence and the conjugated fluorophore. 
Moreover, selective intracellular accumulation of the protein-targeted probes to enable the 
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discrimination of individual healthy and PDAC cells is rare.52 In contrast, probe 12 
possesses inherent pancreas and PDAC mitochondria specificity without the need for 
modification or target conjugation.  
In addition to image guided surgery, a major motivation for designing PDAC 
probes is to facilitate early detection. The 5-year survival rate of patients with PDAC is < 
8%.1 Because most cases are diagnosed in the late stages, < 20 % of all patients have 
resectable tumors.4 Early detection is of paramount importance as early-stage PDAC 
surgery can result in 4-year survival rates of up to 78%, a vast improvement over today’s 
survival rate.55 This has prompted the investigation of fluorescent probes for the ability to 
target PDAC as well as pancreatic intraepithelial neoplasia (PanIN), the lesions that occur 
in the pancreatic ducts that are preinvasive precursors of PDAC.56 In addition to pancreatic 
ductal epithelial cells, there is growing evidence that the transdifferentiation of alternative 
pancreatic cell types, such as acinar cells, embodies an alternative pathway to PDAC. 37-41  
Compound 12 stains acinar cells as well as PDAC-associated ductal epithelial cells (Fig. 
6.4), thus it has potential utility in investigating PDAC progression and early detection. 
At the intracellular level, compound 12 (as well as 13) targets mitochondria in 
PDAC cells (Fig. 4.5 and 4.6). Mitochondrial dysfunction is central to the pathogenesis of 
PDAC.43,44 For example, cells surviving oncogene ablation have been found to be 
responsible for PDAC tumor relapse, and are strongly reliant on mitochondrial respiration 
rather than on glycoloysis.57 There are, moreover, several ongoing investigations of 
therapeutic strategies for PDAC involving modulation of mitochondrial function.57-60 
In conclusion, the synthesis of a focused probe library with predictable 
physicochemical properties afforded a simple molecular probe (12) enabling the imaging 
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of PDAC in a genetically engineered mouse model. Conjugation to a biological targeting 
agent was not required for PDAC tumor specificity. The fluorescent probe functioned at 
the level of the whole organ, enabling visualization of a cancerous pancreas with excellent 
SBR. It targeted PDAC tissue and cells as evidenced by comparison with H&E staining 
and immunohistochemistry, and allowed for ready distinction between individual cell 
morphologies. At the subcellular level, it demonstrated accumulation in the mitochondria. 
Compound 12 is thus a unique tool, enabling the imaging of PDAC at four different levels 
of structure in a genetically engineered mouse model. It thus possesses desirable properties 
for promoting more refined pancreatic cancer detection, therapeutic monitoring and image-




CHAPTER 8. METHODS 
 
8.1       Physicochemical Property Prediction and Molecular Modeling. 
Physicochemical partition coefficients (Log D) values at pH 7.4, were calculated 
using Marvin and JChem calculator plugins (ChemAxon, Budapest, Hungary). Molecular 
orbital, UV-Vis spectra and electrostatic maps calculations were performed using Density 
Functional Theory (DFT) modeling on gas-phase B3LYP/6-31G optimized geometries 
using Gaussian 09.61 
8.2       Synthesis of Fluorescent Probes. 
Seminaphthofluorescein, seminaphthorhodafluors and seminaphthorhodamines 
(Fig. 1.1) were synthesized in two to three steps. The initial step involved the condensation 
of hydroxybenzophenones with the corresponding naphthols in a mixture of 
CH3SO3H:TFA 1:1 at 80 C for 16-24 h to produce the lactones or carboxylates. 
Subsequent Fisher esterification to produce the methyl esters derivatives was carried out 
in MeOH catalyzed by either H2SO4 or HCl. Further alkylation was attained by treatment 
of either the carboxylate or methyl ester intermediate with methyl iodide in the presence of 
K2CO3 in DMF to produce the corresponding methyl ethers. The required starting 
materials; 2-(2,4-dihydroxybenzoyl)benzoic acid, 2-(4-amino-2-hydroxybenzoyl)benzoic 
acid, 2-(8-hydroxy-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carbonyl)benzoic 
acid and 1,8-naphthalene derivatives were synthesized according to described or modified 
literature protocols. In general, overall good yields were obtained for most of the 
fluorophores included in this series with the exception of the condensation products 
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between 2-(2,4-dihydroxybenzoyl)benzoic acid and 8-amino naphthol derivatives 7 and 8, 
where the major isolated product corresponded to fluorescein. All compounds were 
isolated by flash column chromatography or preparative TLC, and characterized by NMR 
and HR ESI MS.  
8.3       UV-Vis Absorption and Fluorescence Spectroscopy. 
UV-Vis spectra were collected with a Cary 50 UV-Vis spectrophotometer at rt 
using a reduced volume 1-cm quartz cuvette. Fluorescence spectra were collected on a Cary 
Eclipse fluorescence spectrophotometer (Agilent Technologies). All absorption spectra 
were reference corrected. Fluorescence spectra were corrected for the wavelength 
dependent response of the R928 photomultiplier tube using a manufacturer generated 
correction file. Quantum yields were reported as the average of multiple measurements 
using multiple references. Excitation emission matrices (EEMs) were collected over 
various spectral regions, using 5- or 10-nm step sizes for emission and excitation. The band 
pass for excitation and emission was 5 to 10 nm. 
8.4       Cell Culture.  
The human PDAC cell line Capan-1 was obtained from Dr. Rosalie Sears’s 
laboratory at Oregon Health and Science University (OHSU) and maintained in RPMI 
medium (Gibco) in a humid atmosphere at 37 C with 5% CO2. All media were 
supplemented with 10% (v/v) fetal bovine serum (FBS), and 1% (v/v) 
penicillin/streptomycin. Cell viability was determined by Cell Titer-Blue assay. 
Monolayers of 104 Capan-1 cells were seeded in triplicate in 96 well plates and incubated 
with decreasing concentration from 100 µM of each compounds in growth media 
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containing 10% FBS. After 24 h incubation time, 20 μL of Cell Titer-Blue reagent was 
added into each well and culture cells were incubated for additional 2 h. Fluorescence 
intensity in each well was recorded at 560/590 nm using a SpectraMax M5 Microplate 
Reader. The half maximal inhibitory concentrations (IC50) of 2, 12 and 13 were determined 
from interpolating values in the graph (% cell viability vs. fluorophore concentration). For 
the comparison of cellular uptake rates in Capan-1 cells, the absorbance of the media was 
measured as background, and the absorbance of the supernatant was obtained to determine 
the cellular uptake by using the absorbance of 10 μM fluorophore in cell free media as 
standard reference. 
8.5       In Vitro Live Cell Imaging. 
Monolayers of 104 Capan-1 cells were seeded in triplicate in 8 well plates and 
incubated for 24 h in growth media containing 10% FBS, and allowed to attach. For 
subcellular colocalization experiments, media was extracted and cells were washed with 
PBS, and phenol red-free growth medium was added to each well. Organelle trackers were 
added to each well, and incubated with the fluorophore of interest (final concentration 0.5 
μM) for 1 h. Cells were washed with PBS and fixed with 2% paraformaldehyde (PFA). 
Fluorescence microscopy was carried out using a Zeiss inverted microscope with an 
Axioscan fluorescence camera for imaging. The final concentrations of organelle trackers 
used were: DAPI 0.5 μM, Mito-tracker green 0.5 μM, and ER-tracker green 1 μM. 
8.6       Animals.  
Approval for the use of all animals in this study was obtained from the Institutional 
Animal Care and Use Committee (IACUC) at OHSU. Male CD-1 mice weighing 22-24 g 
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were purchased from Charles River Laboratories (Wilmington, MA). Genetically 
engineering mouse models of PDAC based on the targeted expression of an oncogenic 
KRAS mutation (KRASG12D) in the mouse pancreas were used to model the human disease. 
Mice expressing the KRAS mutation alone, termed “KC mice”, develop the full range of 
intraductal neoplastic lesions (PanINs) that are histologically indistinguishable from 
human PanINs. The mice develop PanINs with 100% penetrance, but these lesions do not 
progress to metastatic disease.62,63 A modification of the KC mouse that was developed in 
the laboratory of Dr. Rosalie Sears (Department of Molecular & Medical Genetics, Oregon 
Health and Science University) was used to more closely model human PDAC. This mouse 
model, termed “KMC mice”, included overexpression of the wildtype Myc oncogene,64,65 
similar to their previously published breast cancer mouse models.66 This pancreatic cancer 
mouse model developed PanIN lesions by 10 weeks of age and rapidly progressed to PDAC 
including metastatic disease, more closely representing the human disease (Sears Lab 
OHSU, unpublished data). Both KC and KMC mice were used to assess compound 12 
accumulation in PDAC. All animals were placed on 5V75 chlorophyll free diet from 
TestDiet (St. Louis, MO) 1 week prior to any imaging studies. Prior to surgery, mice were 
anaesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine (Patterson Veterinary, 
Devens, MA). The peritoneal cavity was surgically exposed by removal of overlaying skin 
and muscle tissue to image fluorophore biodistribution following intravenous injection. 
8.7       Intraoperative Fluorescence Imaging System. 
In vivo murine biodistribution images and macroscopic images of resected tissues 
were acquired using a custom-built small animal imaging system capable of real time color 
and fluorescence imaging. The imaging system consists of a QImaging EXi Blue 
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monochrome camera (Surrey, British Columbia, CA) for fluorescence detection with a 
removable Bayer filter for collecting co-registered color and fluorescence images. A 
PhotoFluor II light source (89 North, Burlington, VT) was focused onto the surgical field 
through a liquid light guide and used unfiltered for white light illumination. For 
fluorescence detection, the light source was filtered with a 545 ± 12.5 nm, 620 ± 30 nm, or 
a 650 ± 22.5 nm bandpass excitation filter for compound 2 and 12, compound 13, and MB 
fluorescence excitation, respectively. Resulting fluorescence was collected with a 605 ± 35 
nm, 700 ± 37.5 nm, or 720 ± 30 nm bandpass emission filter for compound 2 and 12, 
compound 13, and MB image collection, respectively. All filters were obtained from 
Chroma technology (Bellows Falls, VT). Camera exposure times ranged from 50 to 200 
ms for fluorescence image collection. All images collected for comparison between 
treatment groups were acquired with the same exposure time and are displayed under equal 
normalized brightness and contrast levels where indicated. 
8.8       Systemic Administration of Fluorescent Compounds. 
For initial in vivo testing and biodistribution studies 100 nmol of compounds 2, 12, 
and 13 were injected systemically. Fluorophores were diluted in PBS. For comparison with 
previous studies,7 120 nmol MB was injected systemically. Mice were administered blank 
PBS for control images (n = 3 mice per group, 5 groups). For PDAC tumor mice model 
testing 100 nmol of compound 12 was injected systemically (n = 5 mice). 
8.9       In Vivo Biodistribution Imaging. 
The biodistribution of compounds 2, 12, and 13 was assessed using the 
intraoperative fluorescence imaging system to collect images of the peritoneal cavity. The 
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peritoneal cavity was exposed and images were collected so that the bladder, adipose tissue, 
intestine, kidney, liver, muscle, pancreas, spleen, and stomach were visible within the field 
of view. For initial biodistribution studies images were collected immediately after 
injection and at 5, 15, 30, 60, 120, and 240 min following injection. For MB injected mice, 
images were collected on the same time course, but only out to 60 min due to the rapid 
clearance of methylene blue.7 For PDAC tumor bearing mice, images were collected 
immediately after injection and at 5, 15, 30, 60, and 90 min following injection. Vehicle 
injected control animals were imaged on the same time course as fluorophore injected 
animals for initial testing or immediately following injection only for studies involving MB 
or PDAC tumor bearing mice to assess tissue autofluorescence for comparison to injected 
animals.  
Fluorophore biodistribution kinetics were measured using region of interest 
analysis on images collected of the peritoneal cavity. Mean fluorescence intensities in each 
organ or tissue type were measured from images collected at each time point. All intensities 
were normalized to the muscle intensity at that time point by dividing by the measured 
muscle intensity. Using the normalized fluorescence intensities for each organ or tissue 
type, mean intensities were calculated for each group.  
Upon completion of initial biodistribution studies, animals were euthanized and 
their organs were resected. Macroscopic images of the resected organs were collected using 
the intraoperative fluorescence imaging system and the mean fluorescence intensity of each 
resected organ was measured using region of interest analysis. Fluorescence intensities 
were normalized to the muscle intensity in the same manner as in vivo measurements. Mean 
intensities were calculated for each group using the normalized values. For biodistribution 
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studies in PDAC tumor bearing mice, only the pancreas was resected and imaged following 
euthanasia. 
8.10      Ex Vivo Fluorescence Microscopy, Pathology, and Immunofluorescence 
Staining. 
Resected pancreas tissue from compound 12 in vivo biodistribution studies with 
PDAC tumor bearing mice was fixed with 2% PFA for 12 h, flash frozen in optimal cutting 
temperature (OCT) compound with liquid nitrogen, and stored at -80 °C. Cryosections 
were cut at 10 μm onto Superfrost Plus slides (Fisherbrand, Fisher Scientific). Slides were 
mounted with Fluoromount-G (Southern Biotech, Birmingham, AL) and coverslipped. 
Serial sections were obtained for cytokeratin immunofluorescence microscopy enabling 
imaging of compound 12 and immunofluorescence labeling with 0.01 mg/mL of directly 
labeled anti-pan cytokeratin conjugated to AlexaFluor 488 (eBioscience, San Diego, CA). 
Briefly, slides were rinsed with PBS for 2 min to remove residual OCT. Then, slides were 
fixed by immersion in 2% PFA for 15 min and washed with PBS for 5 min three times. 
Primary antibody was incubated on the slides for 1 h at room temperature. Following 
incubation, slides were washed with PBS three times for 5 min each and then post-fixed 
with PFA for 15 min and washed with PBS once for 5 min before mounting with 
Fluoromount-G. For cytokeratin immunofluorescence controls, serial sections were stained 
using the above immunofluorescence procedure but without antibody present in the 
staining solution that was incubated on the slides. For H&E pathological analysis, slides 
previously stained for cytokeratin expression were unmounted and rinsed with PBS to 
remove residual mounting media prior to H&E staining. Images were acquired on an Axio 
Observer inverted fluorescence microscope (Zeiss, Thornwood, NY) at 10, 20, or 40x 
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magnification. A PhotoFluor II was used unfiltered for H&E color images and filtered 
using a 545 ± 12.5 nm or 470 ± 20 nm bandpass excitation filter for compound 12 or Atto 
488 excitation, respectively. Color images were collected using an Axiocam 105 camera 
(Zeiss) and fluorescence images were collected using an Axiocam 506 camera (Zeiss) 
where a 605 ± 35 nm or 525 ± 25 nm bandpass emission filter was used for compound 12 
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Figure A1 1H NMR spectrum of compound 15 
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Figure A4 1H NMR spectrum of compound 17 
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Figure A5 13C NMR spectrum of compound 17 
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Figure A7 1H NMR spectrum of compound 20 
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Figure A11 13C NMR spectrum of compound 22  
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Figure A13 1H NMR spectrum of compound 24 
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Figure A16 13C NMR spectrum of compound 26 
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Figure A19 13C NMR spectrum of compound 28 
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Figure A21 1H NMR spectrum of compound 31 
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Figure A24 1H NMR spectrum of compound 32 
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Figure A28 13C NMR spectrum of compound 3 
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Figure A30 1H NMR spectrum of compound 33 
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Figure A33 1H NMR spectrum of compound 4 
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Figure A36 1H NMR spectrum of compound 34 
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Figure A39 1H NMR spectrum of compound 5 
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Figure A42 1H NMR spectrum of compound 6 
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Figure A43 1H NMR spectrum of compound 6 
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Figure A45 1H NMR spectrum of compound 7 
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Figure A46 13C NMR spectrum of compound 7 
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Figure A48 1H NMR spectrum of compound 8 
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Figure A49 13C NMR spectrum of compound 8 
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Figure A51 1H NMR spectrum of compound 37 
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Figure A52 13C NMR spectrum of compound 37 
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Figure A54 1H NMR spectrum of compound 9 
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Figure A58 13C NMR spectrum of compound 38 
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Figure A60 1H NMR spectrum of compound 10 
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Figure A69 1H NMR spectrum of compound 12  
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Figure A72 1H NMR spectrum of compound 40 
 152 
Figure A73 13C NMR spectrum of compound 40 
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Figure A75 1H NMR spectrum of compound 13 
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Figure A76 13C NMR spectrum of compound 13 
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Figure A77 HR ESI positive mode spectrum of compound 13 
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